Guardant Health (GH) PT Raised to $155 at BTIG

BTIG analyst Mark Massaro raised the price target on Guardant Health (NASDAQ: GH) to $155.00 (from $145.00) while maintaining a Buy rating.

The analyst comments "Last week, we had the privilege of hosting Guardant Health’s co-founder, co-CEO AmirAli Talasaz, CFO Mike Bell and VP of IR Zarak Khurshid for a full day of upbeat investor meetings. Given that the meetings were held the day of its landmark FDA approval of Guardant360CDx, much of the focus centered on why the FDA approval is so important to the business. Guardant Health remains our Top Pick, we reiterate our Buy rating and we raise our PT from $145 to $155."

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• Texas AG Paxton announces ongoing investigation into Carnival over data breach
• FDA launches Operation TrialBlazer to accelerate drug research